How Analysts Feel About Nabriva Therapeutics Plc Ord Ire (NASDAQ:NBRV) After Decrease in Sellers?

July 17, 2017 - By Henry Gaston

 How Analysts Feel About Nabriva Therapeutics Plc Ord Ire (NASDAQ:NBRV) After Decrease in Sellers?

The stock of Nabriva Therapeutics Plc Ord Ire (NASDAQ:NBRV) registered a decrease of 0.56% in short interest. NBRV’s total short interest was 88,900 shares in July as published by FINRA. Its down 0.56% from 89,400 shares, reported previously. With 16,400 shares average volume, it will take short sellers 5 days to cover their NBRV’s short positions. The short interest to Nabriva Therapeutics Plc Ord Ire’s float is 1.32%.

About 71,993 shares traded or 312.90% up from the average. Nabriva Therapeutics PLC – ADR (NASDAQ:NBRV) has risen 15.31% since July 17, 2016 and is uptrending. It has underperformed by 1.39% the S&P500.

Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The company has market cap of $283.66 million. The Firm is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. It currently has negative earnings. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.

Nabriva Therapeutics PLC – ADR (NASDAQ:NBRV) Ratings Coverage

Among 5 analysts covering Nabriva Therapeutics (NASDAQ:NBRV), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Nabriva Therapeutics had 8 analyst reports since October 12, 2015 according to SRatingsIntel. Leerink Swann initiated the stock with “Outperform” rating in Tuesday, October 13 report. The rating was maintained by Wedbush with “Outperform” on Wednesday, February 1. Leerink Swann reinitiated the stock with “Outperform” rating in Thursday, October 27 report. The stock of Nabriva Therapeutics PLC – ADR (NASDAQ:NBRV) earned “Outperform” rating by Wedbush on Tuesday, October 13. On Wednesday, January 27 the stock rating was initiated by Gabelli with “Buy”. As per Monday, October 12, the company rating was initiated by Needham. RBC Capital Markets initiated Nabriva Therapeutics PLC – ADR (NASDAQ:NBRV) rating on Tuesday, October 13. RBC Capital Markets has “Outperform” rating and $21 target. The rating was maintained by RBC Capital Markets on Thursday, November 12 with “Outperform”.

Another recent and important Nabriva Therapeutics PLC – ADR (NASDAQ:NBRV) news was published by which published an article titled: “Nabriva Therapeutics PLC” on May 21, 2015.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.